Rebinyn Email Program
Email 1, subject line 1: A new treatment option for your patients Sent on: Nov 11, 2017 at 10am EST Same email, resent: Email 1, subject line 2: FDA Approved for 2018: Rebinyn® (Coagulation Factor IX [Recombinant], GlycoPEGylated) Sent On: Jan 21, 2018 at 4pm EST Email 2 subject line: Now available: Rebinyn® (Coagulation Factor IX [Recombinant], GlycoPEGylated) Continue reading
